Aligos Therapeutics (Nasdaq: ALGS) has announced positive top-line results from the Phase IIa HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction ...

BioXcel Therapeutics has announced a clinical reprioritization, focusing on late-stage development of its agitation treatment ...

Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...

Edgewise Therapeutics has reported positive top-line results for its HCM treatment candidate, EDG-7500, boosting shares by ...

Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...

The US Food and Drug Administration yesterday approved a new indication for Rybrevant (amivantamab-vmjw), from Johnson & ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

The Israeli Ministry of Health (IL MOH) has approved Tevimbra (tislelizumab) as monotherapy for the treatment of adult ...

GC Therapeutics (GCTx) has launched with its TFome platform, developed by scientists at Harvard and the Wyss Institute, ...

US companies Incyte and Syndax Pharmaceuticals today announced results from the pivotal Phase II AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

A US biotech that discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. Augmenta uses advanced automation, microfluidics, high ...